<DOC>
	<DOCNO>NCT00491556</DOCNO>
	<brief_summary>This study propose evaluate pre-DHHS guideline HAART initiation de-intensification management strategy adolescent mild immunosuppression compare change CD4 % baseline week 48 de-intensification .</brief_summary>
	<brief_title>Preservation Expansion T-cell Subsets Following HAART De-intensification Atazanavir/Ritonavir ( ATV/r )</brief_title>
	<detailed_description>This randomize , proof concept study youth 18- 24 year age confirm HIV age 9 CD4+ T cell 350 cells/mm3 randomize 3:1 begin HAART consist TDF/FTC/ATV/r ( prefer ) , AZT/3TC/ATV/r , recommend NRTI backbone ATV/r upon entry begin treatment current DHHS guideline . Subjects experimental group achieve virologic control week 24 maintain good control 48 week de-intensify ATV/r alone follow two year . Subjects randomize standard care arm begin HAART TDF/FTC/ATV/r ( prefer ) , AZT/3TC/ATV/r , recommend ATV/r base HAART regimen accord current DHHS standard care .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<criteria>Inclusion Criteria 1 . Age 18 yr 0 day 24 yrs 364 day ; 2 . CD4+ T cell &gt; 350/mm3 HIV RNA ≥ 1,000 copies/ml determine two consecutive measure within 6 month entry second measure collect preentry ; 3 . Infected age 9 . HIV1 infection document licensed ELISA test kit confirm Western blot , HIV1 culture , HIV1 antigen , plasma HIV1 RNA , second antibody test method ELISA time prior entry ; Note : Subjects acute seroconversion evidence ELISA negative ( antibody negative ) DNA PCR HIV1 RNA positive ELISA positive Western Blot indeterminate eligible . 4 . Subjects must naïve ARV medication except woman receive HAART prevention maternal child transmission ( MTCT ) meet follow criterion : HAART ( define three medication two class ) give six month prevention MTCT , Evidence viral suppression HAART regimen define plasma RNA level level detection assay use site either third trimester around time delivery , A minimum six month since HAART exposure prevention MTCT , Exposure HAART single pregnancy ; Note : Prior treatment Trizivir prevention MCTC also permit long viral suppression document time delivery last trimester , whichever recent . 5 . HIV genotype without major resistance mutation ATV/r . The following genotypic mutation exclude subject participation ATN 061 : Major ATV mutation I50L ; I84V ; N88D/S , Major PI mutation include : D30N ; V32I ; L33I/F/V ; M46I/L ; I47V/A ; G48V ; I50V/L ; I54V/L/A/M/T/S ; L76V ; V82A/F/T/S/L ; L90M , Any major PI mutation define current IASUSA Drug Resistance Mutations Figures would adversely affect subject 's future PI choice , Major RT mutation : Q151M 69 insertion complex ; Decisions regard selection NRTI backbone subject NRTI resistance mutation describe make site PI consultation protocol chair designee . Whenever possible otherwise contraindicate , NRTI choices congruent protocolspecified preferred regimen . The site PI must provide copy genotype analysis along propose regimen review ; Note : Subjects go onto either FTC/TDF AZT/3TC must regimen approve protocol team follow preentry screen prior study entry . Note : All HIV1 genotype profile ANY resistance mutation must evaluate physician specialize care HIVinfected patient prior final determination subject eligibility . Polymorphism mutation NOT report since clinical significance unknown . All ( major minor ) mutation appropriately categorize report indicated case report form . In circumstance numerous mutation concern present , consultation protocol team evaluate physician via ATN QNS highly encourage . 6 . Calculated creatinine clearance ≥60 mL/min estimate CockcroftGault equation : For men , ( 140 age year ) x ( body weight kg ) ÷ ( serum creatinine mg/dL x 72 ) = CrCl ( mL/min ) * ; *For woman , multiply result 0.85 = CrCl ( mL/min ) ; 7 . For female childbearing potential , agreement use one effective birth control method willing postpone pregnancy duration study ( See Section 9.3 criterion class C drug follow ) ; 8 . Able provide write informed consent/assent . Exclusion Criteria 1 . Pregnancy ; 2 . On systemic immunosuppressive therapy immune modulate therapy ( short course ( &lt; 14 day ) prednisone reactive airway disease [ RAD ] permit within 30 day prior study entry ) ; 3 . Any history AIDSdefining illness ( note : history CD4 + T cell count 200 cells/mm3 exclusion criterion long inclusion/exclusion criterion meet ) ; 4 . Currently breast feeding ; 5 . Current treatment active serious systemic bacterial infection ; 6 . Active hepatitis B infection define Hepatitis B Ag positive ; 7 . Treatment immune modulators include IL2 , intravenous gammaglobulin , therapeutic experimental vaccine include HIV1 vaccine give primary prevention time ; 8 . History cardiac conduction abnormality include one following : Symptomatic heart block , Thirddegree heart block , even asymptomatic , Preexcitation syndromes , Heart Rate &lt; 40 bpm , Ventricular pause length &gt; 3 second , QTc &gt; 500 msec , Cardiomyopathy ; 9 . Disallowed Medications ( see Section 5.3.2 ) ; 10 . Active drug alcohol use dependence , opinion site personnel , would interfere adherence study ; 11 . History chronic renal insufficiency Grade 3 great serum creatinine ; 12 . Any confirm grade 3 great laboratory value preentry ( exception grade 3 great lipid platelet ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Atazanavir/Ritonavir ( ATV/r )</keyword>
	<keyword>highly-active antiretroviral therapy ( HAART )</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>